The influence of stromal cells and tumor-microenvironment-derived cytokines and chemokines on CD3+CD8+ tumor infiltrating lymphocyte subpopulations

OncoImmunology

Volumn 6, Issue 6, 2017, Pages

  Koeck, Stefan ^a,b   Kern, Johan ^a,b   Zwierzina, Marit ^a   Gamerith, Gabriele ^a,b   Lorenz, Edith ^a,b   Sopper, Sieghart ^a,b   Zwierzina, Heinz ^a,b   Amann, Arno ^a,b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

3D; biomarker; cancer; co culture; cytokines; immune cells; infiltration; microenvironment; subpopulation

Indexed keywords

CUTANEOUS T CELL ATTRACTING CHEMOKINE; CXCL11 CHEMOKINE; CXCL13 CHEMOKINE; CXCL9 CHEMOKINE; FRACTALKINE; INTERLEUKIN 12P70; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR; UVOMORULIN;

ARTICLE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CRYOPRESERVATION; CYTOKINE RELEASE; CYTOTOXIC LYMPHOCYTE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; LIMIT OF QUANTITATION; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; STROMA CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 85020740512     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1323617     Document Type: Article

References (29)

1. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14(10):1014-22; PMID:24048123; https://doi.org/10.1038/ni.2703
2. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352(8):786-92; PMID:15728811; https://doi.org/10.1056/NEJMoa044238
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353(2):123-32; PMID:16014882; https://doi.org/10.1056/NEJMoa050753
4. Ma PC. Personalized targeted therapy in advanced non-small cell lung cancer. Cleve Clin J Med 2012; 79(Electronic Suppl 1):eS56-60; PMID:22614968; https://doi.org/10.3949/ccjm.79.s2.12
5. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009; 373(9668):1033-40; PMID:19304016; https://doi.org/10.1016/S0140-6736(09)60251-8
6. Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who's who of T-cell differentiation:Human memory T-cell subsets. Eur J Immunol 2013; 43(11):2797-809. Epub 2013 Oct 30; PMID:24258910; https://doi.org/10.1002/eji.201343751
7. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353(25):2654-66; PMID:16371631; https://doi.org/10.1056/NEJMoa051424
8. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004; 6(1):17-32; PMID:15261139; https://doi.org/10.1016/j.ccr.2004.06.010
9. Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L, Chiarugi P. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res 2010; 70(17):6945-56. Epub 2010 Aug 10; PMID:20699369; https://doi.org/10.1158/0008-5472.CAN-10-0785
10. Soon PS, Kim E, Pon CK, Gill AJ, Moore K, Spillane AJ, Benn DE, Baxter RC. Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells. Endocr Relat Cancer 2013; 20(1):1-12. Print 2013 Feb; PMID:23111755; https://doi.org/10.1530/ERC-12-0227
11. Kunz-Schughart LA, Knuechel R. Tumor-associated fibroblasts (part II):Functional impact on tumor tissue. Histol Histopathol 2002; 17(2):623-37; PMID:11962762.
12. Karagiannis GS, Poutahidis T, Erdman SE, Kirsch R, Riddell RH, Diamandis EP. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol Cancer Res 2012; 10(11):1403-18; PMID:23024188; https://doi.org/10.1158/1541-7786.MCR-12-0307. Epub 2012 Sep 28.
13. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4(1):11-22; PMID:14708024; https://doi.org/10.1038/nrc1252
14. Nolz JC, Starbeck-Miller GR, Harty JT. Naive, effector and memory CD8 T-cell trafficking:Parallels and distinctions. Immunotherapy 2011; 3(10):1223-33; PMID:21995573; https://doi.org/10.2217/imt.11.100
15. Stein JV, Nombela-Arrieta C. Chemokine control of lymphocyte trafficking:A general overview. Immunology 2005; 116(1):1-12; PMID:16108812; https://doi.org/10.1111/j.1365-2567.2005.02183.x
16. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313(5795):1960-4; PMID:17008531; https://doi.org/10.1126/science.1129139
17. Chockley PJ, Keshamouni VG. Immunological consequences of epithelial–mesenchymal transition in tumor progression. J Immunol 2016; 197(3):691-8; PMID:27431984; https://doi.org/10.4049/jimmunol.1600458
18. Mele V, Muraro MG, Calabrese D, Pfaff D, Amatruda N, Amicarella F, Kvinlaug B, Bocelli-Tyndall C, Martin I, Resink TJ, et al. Mesenchymal stromal cells induce epithelial-to-mesenchymal transition in human colorectal cancer cells through the expression of surface-bound TGF-β. Int J Cancer 2014; 134(11):2583-94; PMID:24214914; https://doi.org/10.1002/ijc.28598
19. Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C, et al. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin Cancer Res 2016; 22(14):3630-42; PMID:26851185; https://doi.org/10.1158/1078-0432.CCR-15-1434
20. Amann A, Zwierzina M, Gamerith G, Bitsche M, Huber JM, Vogel GF, Blumer M, Koeck S, Pechriggl EJ, Kelm JM, et al. Development of an innovative 3D cell culture system to study tumour–stroma interactions in non-small cell lung cancer cells. PLoS One 2014; 9(3):e92511. eCollection 2014; PMID:24663399; https://doi.org/10.1371/journal.pone.0092511
21. Koeck S, Zwierzina M, Huber JM, Bitsche M, Lorenz E, Gamerith G, Dudas J, Kelm JM, Zwierzina H, Amann A. Infiltration of lymphocyte subpopulations into cancer microtissues as a tool for the exploration of immunomodulatory agents and biomarkers. Immunobiology 2016; 221(5):604-17. Epub 2016 Feb 1; PMID:26876590; https://doi.org/10.1016/j.imbio.2015.12.010
22. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006; 211:214-24; PMID:16824130; https://doi.org/10.1111/j.0105-2896.2006.00391.x
23. Fujita M, Takada YK, Takada Y. Integrins αvβ3 and α4β1 act as co-receptors for fractalkine and the integrin-binding defective mutant of fractalkine is an antagonist of CX3CR1. J Immunol 2012; 189(12):5809-5819; PMID:23125415; https://doi.org/10.4049/jimmunol.1200889
24. Tan KW, Evrard M, Tham M, Hong M, Huang C, Kato M, Prevost-Blondel A, Donnadieu E, Ng LG, Abastado JP. Tumor stroma and chemokines control T-cell migration into melanoma following Temozolomide treatment. Oncoimmunology 2015; 4(2):e978709. eCollection 2015; PMID:25949877; https://doi.org/10.4161/2162402X.2014.978709
25. Clemente CG, Mihm MC, Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77(7):1303-10; PMID:8608507; https://doi.org/10.1002/(SICI)1097-0142(19960401)77:7%3c1303::AID-CNCR12%3e3.0.CO;2-5
26. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26(27):4410-7; PMID:18802153; https://doi.org/10.1200/JCO.2007.15.0284
27. Silzle T, Randolph GJ, Kreutz M, Kunz-Schughart LA. The fibroblast:Sentinel cell and local immune modulator in tumor tissue. Int J Cancer 2004; 108(2):173-80; PMID:14639599; https://doi.org/10.1002/ijc.11542
28. Comito G, Giannoni E, Segura CP, Barcellos-de-Souza P, Raspollini MR, Baroni G, Lanciotti M, Serni S, Chiarugi P. Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. Oncogene 2014; 33(19):2423-31. Epub 2013 Jun 3; PMID:23728338; https://doi.org/10.1038/onc.2013.191
29. Harper J, Sainson RC. Regulation of the anti-tumour immune response by cancer associated fibroblasts. Semin Cancer Biol 2014; 25:69-77. Epub 2014 Jan 7; PMID:24406209; https://doi.org/10.1016/j.semcancer.2013.12.005